Table 4.
Treatment related adverse events, n (%)
|
|
TT group (n = 1011)
|
CT group (n = 972)
|
P
value
|
| Eradication related Side effects | < 0.001 | ||
| No | 78 (77.23) | 48 (49.48) | |
| Yes | 23 (22.77) | 49 (50.52) | |
| Taste disturbance | 2 (1.98) | 18 (18.56) | |
| Nausea/vomiting | 10 (9.90) | 15 (15.46) | |
| Diarrhea/loose stool/constipation | 6 (5.94) | 9 (9.28) | |
| Abdominal discomfort, dyspepsia | 3 (2.97) | 3 (3.09) | |
| General weakness, myalgia | 1 (0.99) | 1 (1.03) | |
| Dizziness, headache | 1 (0.99) | 2 (2.06) | |
| Skin rash | 0 (0.00) | 1 (1.03) |
1
Of the 110 patients who were initially allocated into the tailored therapy (TT) group, 9 were not followed up. Therefore, a total of 101 patients were included in the TT group.
2
Of the 107 patients who were initially allocated into the concomitant therapy (CT) group, 10 were lost to follow up. Therefore, a total of 97 patients were included in the CT group, regardless of compliance status. TT: Tailored therapy; CT: Concomitant therapy.